Office of Research Development
Limited Submission Funding Opportunity
Centers for Disease Control and Prevention

Annual Estimates of Influenza Vaccine Effectiveness for Preventing Medically Attended Laboratory-Confirmed Influenza in the United States

http://www.grants.gov/web/grants/view-opportunity.html?oppId=279983

FOA#: RFA-IP-16-002

The goal of this FOA is to support a network of US institutions that can obtain reliable vaccination information for a population and provide accurate estimates of annual influenza vaccine effectiveness (VE) to prevent influenza-associated illness in that population. Participating institutions will coordinate enrollment of patients with acute respiratory illness (ARI), confirm influenza infection using a standardized reverse-transcription PCR (RT-PCR) assay, and estimate VE using a test-negative study design. Interim VE estimates during the influenza season and end-of-season VE estimates will be used to inform vaccine recommendations and assess public health impact of influenza vaccination programs to prevent influenza-related illness and medical visits among persons of all ages. In addition, this network will compare VE for specific vaccine types available in the US. This network will serve as an emergency response resource in the event of an influenza pandemic to assess VE to prevent medically-attended illness associated with pandemic influenza.

Each application MUST address the Core Component and the two Additional Components.

A. Core Component for Years 1-5 ($800,000 per year):

Assess influenza vaccine effectiveness (VE) in preventing laboratory-confirmed influenza infections among children and adults with medically-attended, acute respiratory illness (MAARI) who present for care in ambulatory settings.

B. Two Additional Components for Years 3-5 ($100,000 each, thus $200,000 total per year):
1) Evaluation of disease burden due to respiratory syncytial virus (RSV) and other respiratory viruses during the influenza season

2) Pandemic Preparedness

In the event of an influenza pandemic, participating sites would be involved in pandemic response activities, including studies to describe the epidemiology of novel influenza virus infection and burden of disease, and to evaluate use and effectiveness of antiviral agents for treatment and effectiveness of seasonal and pandemic influenza vaccines for prevention of pandemic influenza.

LIMIT ON NUMBER OF PROPOSALS PER ORGANIZATION
Only one application per institution is allowed.

KEY DATES
If you are interested in this funding opportunity, please send a one-page summary of the proposed research and your biosketch to Eric Boberg (e-boberg@northwestern.edu) by November 23, 2015.

Sponsor letter of intent due date: December 14, 2015
Sponsor application due date: January 11, 2016

COLLABORATION OPPORTUNITIES
The Office of Research Development offers assistance in identifying and facilitating collaborations, putting together interdisciplinary teams, programmatic and administrative development of large, cross-school proposals, and leveraging institutional resources for outreach and education. Contact Fruma Yehiely (yehiely@northwestern.edu), Associate Vice President for Research, Director of ORD, for more information.

CONTACT AND ADDITIONAL INFORMATION
Fruma Yehiely, Associate Vice President for Research, Director of ORD, 847-491-1074, yehiely@northwestern.edu
Limited Submissions web site: www.research.northwestern.edu/ord/funding/limited-submissions/